| 刊名 | Medicinal Plant |
| 作者 | Qi TANG， Xingxiang LIAO， Feng CAO， Li CHEN， Fenglan HUANG |
| 作者单位 | No.4 West China Teaching Hospital, Sichuan University； Sichuan Raybo Biotechnology Co., Ltd. |
| DOI | 10.19601/j.cnki.issn2152-3924.2025.04.016 |
| 年份 | 2025 |
| 刊期 | 4 |
| 页码 | 63-65,76 |
| 关键词 | Bone collagen peptide (BCP), Knee osteoarthritis (KOA), Random, Comparison, Clinical trial |
| 摘要 | [Objectives] To explore the impact of bone collagen peptide (BCP) on patients with knee osteoarthritis (KOA). [Methods] A total of 100 patients diagnosed with KOA were admitted to the study and randomly assigned to either a control group or a treatment group, with each group comprising 50 participants. The control group received health education along with standard daily treatment protocols. In contrast, the treatment group was administered an additional dosage of 20 g of BCP twice daily, in conjunction with the treatment regimen provided to the control group. Both groups received continuous treatment for 3 months. The WOMAC scores and the WHOQOL-BREF scores of the participants in both groups were assessed both prior to and following treatment. [Results] Following treatment, the WOMAC scores of patients in the treatment group demonstrated a significant improvement compared to those in the control group (13.39±2.19 vs. 15.46±1.30, P<0.05). Additionally, the WHOQOL-BREF scores for patients in both groups showed improvement, with the treatment group exhibiting superior WHOQOL-BREF scores relative to the control group (P<0.05). [Conclusions] For patients diagnosed with KOA, the supplementation of BCP alongside conventional treatment has been shown to significantly enhance knee joint function and improve the overall quality of life for these individuals. |
